Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2009-02-10 Interim / Quarterly Rep…
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
LCT reports substained benefit with DIABECELL 2 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is a company announcement reporting interim clinical trial results for a product (DIABECELL) related to insulin dependent diabetes. It provides detailed data on patient outcomes, dosage, and follow-up periods, indicating substantive content rather than a brief announcement or a regulatory filing. The document is dated February 11, 2009, and includes specific interim results with clinical data such as HbA1c levels and insulin dose reductions. There is no indication that this is a full annual report or audit report, nor is it a transcript, capital update, or legal proceeding. The content fits the definition of an Interim / Quarterly Report (IR) as it provides comprehensive results for a period shorter than a full fiscal year with substantive data and analysis. The document length (7248 characters) supports it being a report rather than a brief announcement. Therefore, the most appropriate classification is Interim / Quarterly Report (IR). H1 2009
2009-02-10 English
Appendix 4C - quarterly 7 pages ?Kb
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly Report' and contains detailed quarterly cash flow information for the period ended 31 December 2008. It includes consolidated statements of cash flows, cash balances, operating, investing, and financing activities, payments to directors, and compliance statements. The document is approximately 13,500 characters long, indicating it is a substantive financial report rather than a brief announcement. The presence of detailed financial data and analysis for a quarter strongly indicates this is an Interim / Quarterly Report. The document is not merely an announcement of a report or a certification, but the actual quarterly financial report itself. Therefore, the appropriate classification is 'IR' (Interim / Quarterly Report). Q2 2009
2009-01-29 English
Change of Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including number of shares held before and after the change, nature of the change (on-market trade), and dates. This type of document is a regulatory filing specifically reporting personal share transactions by company directors and executives, commonly known as insider trades. It is not a financial report, earnings release, or management announcement. Therefore, the correct classification is Director's Dealing (DIRS). The document length and content fully support this classification with high confidence.
2009-01-20 English
Change in substantial holding 2 pages ?Kb
Regulatory Filings
2009-01-15 English
Cash conservation and change of CEO 2 pages ?Kb
Board/Management Information Classification · 100% confidence The document is a company announcement dated December 23, 2008, regarding a change in the company's management: the CEO Dr. Robert Caspari is stepping down but remains on the Board, and Dr. Paul Tan resumes CEO responsibilities. The content focuses on management changes and operational strategy, with no financial statements or detailed financial data. It is not a full annual or interim report, nor an earnings release or investor presentation. The document is not a regulatory filing or certification. Therefore, it fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2008-12-22 English
Collaboration with Centocor Research and Development Inc 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a company announcement dated December 18, 2008, about Living Cell Technologies entering a research collaboration agreement with Centocor Research & Development, Inc. It describes the nature of the collaboration and the company's technology but does not contain any financial data, regulatory filings, or detailed reports. The document is relatively short (5206 characters) and serves as a news release or announcement rather than a financial report or regulatory filing. There is no indication of it being an earnings release, annual report, or any other formal filing type. Therefore, the most appropriate classification is a Regulatory Filing (RNS), which is the fallback category for general company announcements that do not fit other specific categories.
2008-12-17 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.